In this session, researchers, clinicians, and program implementers from four countries will address the disruption in continuity of care for PLHIV amid the COVID-19 pandemic and the consequent implications for drug resistance in individuals on ART. Panelists will highlight their country's progress to 90-90-90 goals pre-pandemic and discuss the current state-of-affairs in reaching the 2030 targets of 95-95-95. Key topics include: lessons learned from COVID-19 and their application to HIV patient monitoring and HIV drug resistance surveillance; opportunities to leverage HIV program structure to expand access to COVID-19 testing and vaccination; and recommended course of action to address gaps in care for PLHIV.